Novoste's Beta-Cath gains FDA approvable letter
This article was originally published in Clinica
Executive Summary
The US FDA has issued Novoste with an approvable letter for its Beta-Cath intracoronary radiation catheter system for treating in-stent restenosis. The Norcross, Georgia-based company said it is making "good progress" towards resolving conditions set down by the FDA and that it could have final approval by mid-November.